China National Medicines Corporation Ltd. (SHA:600511)
China · Delayed Price · Currency is CNY 29.20
+0.29 (1.00%)
Apr 15, 2026, 3:00 PM CST
SHA:600511 Revenue
In the year 2025, China National Medicines Corporation had annual revenue of 52.47B CNY with 3.70% growth. China National Medicines Corporation had revenue of 13.09B in the quarter ending December 31, 2025, with 4.12% growth.
Revenue
52.47B
Revenue Growth
+3.70%
P/S Ratio
0.42
Revenue / Employee
17.35M
Employees
3,024
Market Cap
22.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.47B | 1.87B | 3.70% |
| Dec 31, 2024 | 50.60B | 901.40M | 1.81% |
| Dec 31, 2023 | 49.70B | 4.20B | 9.23% |
| Dec 31, 2022 | 45.50B | -970.02M | -2.09% |
| Dec 31, 2021 | 46.47B | 6.09B | 15.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Pharmaceuticals Holding | 283.58B |
| Jointown Pharmaceutical Group | 157.71B |
| C.Q. Pharmaceutical Holding | 83.08B |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company | 77.66B |
| China National Accord Medicines Corporation | 73.42B |
| China Meheco Group | 33.23B |
| Guangxi LiuYao Group | 20.95B |
| Liaoning Cheng Da | 11.12B |